Cas:414878-36-7 2-[acetyl-[3-(diethylamino)propyl]amino]-N-(2,4,6-trimethylphenyl)propanamide manufacturer & supplier

Chemical Name:2-[acetyl-[3-(diethylamino)propyl]amino]-N-(2,4,6-trimethylphenyl)propanamide

CAS.NO:414878-36-7

Synonyms:2-(n-(3-(diethylamino)propyl)acetamido)-n-mesitylpropanamide

Molecular Formula:C₂₁H₃₅N₃O₂

Molecular Weight:361.52200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:56.14000

Exact Mass:361.27300

LogP:4.16870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(n-(3-(diethylamino)propyl)acetamido)-n-mesitylpropanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(n-(3-(diethylamino)propyl)acetamido)-n-mesitylpropanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(n-(3-(diethylamino)propyl)acetamido)-n-mesitylpropanamide Use and application,2-(n-(3-(diethylamino)propyl)acetamido)-n-mesitylpropanamide technical grade,usp/ep/jp grade.

Related News: GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. 3-Oxocholest-4-en-19-oic Acid manufacturers A major advantage of identifying suitable biocatalysts early on is that it provides ample opportunity for optimization. N-{3-[3-(t-butyldimethylsilyloxy)-17β-(tetrahydro-2H-pyran-2-yl-oxy)-estra-1,3,5(10)-trien-16β-yl]-propyl}-2-(t-butoxycarbonylamino)-acetamide suppliers “In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources. Linseed oil-wood oil-p-phenylphenol formaldehyde resin-coumarone indene resin polymer vendor & factory GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. ,“In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources.